Modular CGRP Antagonist Compounds for Expanded Migraine Options
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine and other CGRP-related disorders are limited, and there is a need for more effective CGRP receptor antagonists to manage these conditions.
Innovation Solution
Development of novel compounds with specific structural formulas that act as CGRP receptor antagonists, including various aryl and heteroaryl groups, linker groups, and optional substitutions, which can be used in pharmaceutical compositions to treat a wide range of disorders involving CGRP receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP treatments (antibodies or small molecules) are used, then migraine treatment is achieved, but treatment options are limited and efficacy may be insufficient for some patients
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters including ring size (5-7 membered rings), substitution patterns (positions 2, 3, 4, 5, 6), heteroatom types (O, NH, NMe), and linker characteristics to generate a series of compounds with different binding affinities and pharmacological profiles, thereby expanding treatment options while maintaining efficacy
Solution Approach 2:
The patent creates a universal compound platform with core structure Formula (1a) that can be adapted through various substitutions to treat multiple CGRP-related conditions including migraine, cluster headache, and other vascular disorders, making the compound class broadly applicable across different indications
2Reliability
If novel compound structures with multiple substitutions are developed, then CGRP receptor antagonism activity is enhanced, but molecular complexity increases
Solution Approach 1:
The patent segments the molecule into distinct functional modules: a core pyridine ring (Formula 1a), optional substituent groups (R1, V, X, Y), and linker groups connecting to additional aromatic systems. This modular segmentation allows systematic optimization of each component's contribution to binding affinity while maintaining overall structural coherence
Solution Approach 2:
The patent constructs composite molecular structures by combining the core pyridine ring with various aromatic substituents and linker groups to create Formula (1b) compounds. These composite structures integrate multiple functional elements that collectively enhance CGRP receptor binding while distributing molecular complexity across manageable structural units
Data Source
AI summary
The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.